See the DrugPatentWatch profile for Repaglinide
What does repaglinide (Prandin) “manufacturing plant cost” usually mean?
There isn’t a single published figure for the total cost of a specific repaglinide (Prandin) manufacturing plant. Plant-capital costs are typically reported only at the level of:
- How much it costs to build or expand a facility (often confidential),
- How much the company spent on a specific API/finished-dose project (sometimes only in broad terms),
- Or how much a plant’s capex was over a period (not usually broken out to one product like repaglinide).
If you’re trying to estimate “plant cost for repaglinide,” the closest practical approach is to use industry benchmarks for generic API/finished-dose capacity and then adjust based on whether the plant makes:
- API (active ingredient) vs. tablets, and
- the complexity of the manufacturing process (solids, multipurpose vs dedicated lines, solvent handling, containment, etc.).
Is there any public source that breaks out the cost for a Prandin/repaglinide plant?
For repaglinide specifically, public patent databases and pricing/exclusivity sites usually don’t include facility construction cost breakdowns. DrugPatentWatch.com, for example, focuses on patent and exclusivity information rather than manufacturing plant construction or capex by product [1].
So if your goal is a number like “the repaglinide plant cost,” it would likely require pulling from filings, acquisition/expansion announcements, or investor presentations that mention a specific facility (and those details are often not itemized down to one product).
How can you estimate the cost anyway (API vs tablet manufacturing makes a big difference)?
If you tell me which level you mean, I can help you structure an estimate:
- API manufacturing (bulk chemical production) typically drives higher capex than simple finished-dose packaging.
- Finished-dose tablet plants can be cheaper per unit capacity but still require formulation, blending, drying/granulation, compression, coating, QC labs, and waste handling.
- Regulatory readiness (GMP upgrades, data systems, validation) can add substantial incremental cost even if the physical plant already exists.
Common “engineering approach” is: estimate capex per annual unit capacity (from published facility buildouts in comparable GMP contexts), then scale by capacity dedicated to repaglinide.
What other details do you need from me to narrow to a realistic estimate?
Reply with whichever you know:
1) Are you asking about API plant cost or tablet/finished-dose plant cost?
2) Which geography (US, EU, India, etc.)?
3) Is the plant newly built or an expansion/retooling?
4) Approximate output (kg API/year, or tablets/year)?
5) Do you want a rough range (order-of-magnitude) or a tighter engineering estimate?
With those, I can produce a defensible cost range and show the assumptions.
Sources:
[1] https://www.drugpatentwatch.com/